Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
08 May 2024 - 9:02PM
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,”
Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused
on the discovery, development and commercialization of targeted
therapies for women’s cancers, today announced that it will present
new clinical data from the Company’s ongoing Phase 1b/2 clinical
study of palazestrant in combination with CDK4/6 inhibitor
ribociclib in a poster presentation at the upcoming European
Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
2024 taking place May 15-17, 2023, in Berlin, Germany.
Details of the ESMO Breast Cancer Annual Congress 2024
poster presentation are:
Title: |
A
Phase 1b/2 study of palazestrant (OP-1250) in combination with
ribociclib in patients with estrogen receptor-positive, human
epidermal growth factor receptor 2-negative (ER+, HER2-), advanced
and/or metastatic breast cancer (ID 407) |
Presentation
#: |
212P |
Date: |
Thursday, May 16, 2024 |
Time: |
12:00 p.m. CEST (6:00 a.m.
ET) |
A copy of the poster will be made available on Olema’s website
under the Science section when it is presented at the congress.
Abstracts for the posters will be found on the ESMO Breast Cancer
Annual Congress website here.
Company Investor Webcast and Conference
Call
Olema will host a webcast and conference call for analysts and
investors to review the data being presented at ESMO Breast Cancer
Annual Congress 2024 on Wednesday, May 15, 2024, at 8:00 a.m. ET
(2:00 p.m. CEST). Please register for the webcast by visiting the
Investors & Media section of Olema’s website at olema.com.
About Palazestrant (OP-1250)
Palazestrant (OP-1250) is a novel, orally-available small
molecule with dual activity as both a complete estrogen receptor
(ER) antagonist (CERAN) and selective ER degrader (SERD). It is
currently being investigated in patients with recurrent, locally
advanced or metastatic ER-positive (ER+), human epidermal growth
factor receptor 2-negative (HER2-) breast cancer. In clinical
studies, palazestrant completely blocks ER-driven transcriptional
activity in both wild-type and mutant forms of metastatic ER+
breast cancer and has demonstrated anti-tumor efficacy along with
attractive pharmacokinetics and exposure, favorable tolerability,
CNS penetration, and combinability with CDK4/6 inhibitors.
Palazestrant has been granted U.S. Food and Drug Administration
(FDA) Fast Track designation for the treatment of ER+/HER2-
metastatic breast cancer that has progressed following one or more
lines of endocrine therapy with at least one line given in
combination with a CDK4/6 inhibitor. It is being evaluated both as
a single agent in an ongoing Phase 3 clinical trial, OPERA-01, and
in Phase 1/2 combination studies with CDK4/6 inhibitors
(palbociclib and ribociclib), a PI3Ka inhibitor (alpelisib), and an
mTOR inhibitor (everolimus). For more information, please visit
www.opera01study.com.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company
committed to transforming the standard of care and improving
outcomes for women living with cancer. Olema is advancing a
pipeline of novel therapies by leveraging our deep understanding of
endocrine-driven cancers, nuclear receptors, and mechanisms of
acquired resistance. In addition to our lead product candidate,
palazestrant (OP-1250), a proprietary, orally-available complete
estrogen receptor (ER) antagonist (CERAN) and a selective ER
degrader (SERD), Olema is developing a potent KAT6 inhibitor
(OP-3136). Olema is headquartered in San Francisco and has
operations in Cambridge, Massachusetts. For more information,
please visit us at www.olema.com.
IR and Media Contact:Geoffrey Mogilner, Vice
President, Investor Relations and Communicationsir@olema.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From May 2024 to Jun 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
From Jun 2023 to Jun 2024